[1] 徐小元、丁惠国、李文刚、贾继东、魏来、段钟平、令狐恩强、庄辉。肝硬化腹水及相关并发症的诊疗指南[J]. 中华实验和临床感染病杂志(电子版),2017,11(05):417-432.
[2] Biggins SW et al; AASLD. Diagnosis, evaluation, and management of ascites and hepatorenal syndrome. Hepatology 2021; doi:10.1002/hep.31884.
[3] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol 2010;53(3):397–417.
[4] Aithal GP et al. Guidelines on the management of ascites in cirrhosis. Gut 2021;70(1):9–29.
[5] Angeli P et al. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites. J Hepatol 2015;62(4):968–74.
[6] Arora V et al. Paracentesis-induced circulatory dysfunction with modest-volume paracentesis is partly ameliorated by albumin infusion in acute-on-chronic liver failure.Hepatology 2020;72(3):1043–55.
[7] Sen Sarma M et al. Safety, complications and outcome of large volume paracentesis with or without albumin therapy in children with severe ascites due to liver disease. J Hepatol 2015;63(5):1126–32.
[8] Fernández J et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis. Gastroenterology 2019;157(1):149-62.
[9] Caraceni P et al. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. Lancet 2018;391(10138):2417–29.
[10] China L et al. A randomized trial of albumin infusions in hospitalized patients with cirrhosis. N Engl J Med 2021;384(9):808–17.
[11] Salerno F, Navickis RJ, Wilkes MM. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. Clin Gastroenterol Hepatol 2013;11(2):123-30.
[12] Thévenot T et al. Effect of albumin in cirrhotic patients with infection other than spontaneous bacterial peritonitis. A randomized trial. J Hepatol 2015;62(4):822-30.
[13] Wong F et al. Terlipressin plus albumin for the treatment of type1 hepatorenal syndrome. N Engl J Med 2021;384(9):818-28.
[14] Gentilini P et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30(4):639–45.
[15] Romanelli RG et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006;12(9):1403-7.
[16] Di Pascoli M et al. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 2019;39(1):98-105.
[17] Bureau C et al. Transjugular intrahepatic portosystemic shunts with covered stents
increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152(1):157–63.
[18] Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15(12):753–64.